Reporting Manager
TANG CAPITAL MANAGEMENT, LLC
Symbol
SYRE
Shares outstanding
60,377,358 shares
Disclosed Ownership
3,200,000 shares
Ownership
5.3%
Form type
SCHEDULE 13G
Filing time
01 May 2025, 16:15:17 UTC
Date of event
24 Apr 2025
Next filing
17 Feb 2026

Quoteable Key Fact

"TANG CAPITAL MANAGEMENT LLC disclosed 5.3% ownership in Spyre Therapeutics, Inc. Common Stock, par value $0.0001 per share (SYRE) on 24 Apr 2025."

Quick Takeaways

  • TANG CAPITAL MANAGEMENT LLC filed SCHEDULE 13G for Spyre Therapeutics, Inc. Common Stock, par value $0.0001 per share (SYRE).
  • Disclosed ownership: 5.3%.
  • Date of event: 24 Apr 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 01 May 2025, 16:15.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (6)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
TANG CAPITAL MANAGEMENT, LLC 5.3% 3,200,000 0 3,200,000 /s/ Kevin Tang Manager
KEVIN TANG 5.3% 3,200,000 0 3,200,000 /s/ Kevin Tang Self
TANG CAPITAL PARTNERS, LP 3% 1,799,658 0 1,799,658 /s/ Kevin Tang Manager, Tang Capital Management, LLC, General Partner
TANG CAPITAL PARTNERS INTERNATIONAL, LP 2.3% 1,400,342 0 1,400,342 /s/ Kevin Tang Manager, Tang Capital Management, LLC, General Partner
TANG CAPITAL PARTNERS III, INC 0% 0 0 0 /s/ Kevin Tang Chief Executive Officer
TANG CAPITAL PARTNERS IV, INC 0% 0 0 0 /s/ Kevin Tang Chief Executive Officer